New Insulin Analogues and Routes of Delivery
暂无分享,去创建一个
[1] P. Brunetti,et al. Improved Postprandial Metabolic Control After Subcutaneous Injection of a Short-Acting Insulin Analog in IDDM of Short Duration With Residual Pancreatic β-Cell Function , 1995, Diabetes Care.
[2] T. Pieber,et al. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[3] P. Home,et al. The Effect of the Insulin Analog Lispro on Nighttime Blood Glucose Control in Type 1 Diabetic Patients , 1998, Diabetes Care.
[4] M. Burge,et al. Meal Composition is a Determinant of Lispro-Induced Hypoglycemia in IDDM , 1997, Diabetes Care.
[5] S. Fineberg,et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. , 2005, The Journal of clinical endocrinology and metabolism.
[6] R. Becker,et al. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique , 2005, Diabetologia.
[7] L. Heinemann. Future directions for insulin therapy and diabetes treatment. , 2007, Endocrinology and metabolism clinics of North America.
[8] P. Brunetti,et al. Effects of the Short-Acting Insulin Analog [Lys(B28),Pro(B29)] on Postprandial Blood Glucose Control in IDDM , 1996, Diabetes Care.
[9] L. Heinemann,et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. , 2005, Diabetes care.
[10] L. Heinemann,et al. Time–action Profile of Inhaled Insulin , 1997, Diabetic medicine : a journal of the British Diabetic Association.
[11] P. Raskin,et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. , 2005, Diabetes care.
[12] J. Shipp,et al. Insulin Across Respiratory Mucosae by Aerosol Delivery , 1971, Diabetes.
[13] W. Cefalu. Concept, strategies, and feasibility of noninvasive insulin delivery. , 2004, Diabetes care.
[14] C. Saudek,et al. Novel forms of insulin delivery. , 1997, Endocrinology and metabolism clinics of North America.
[15] A. Pfützner,et al. Technosphere/Insulin--a new approach for effective delivery of human insulin via the pulmonary route. , 2002, Diabetes technology & therapeutics.
[16] L. Heinemann,et al. No evidence for accumulation of insulin glargine (LANTUS®): a multiple injection study in patients with Type 1 diabetes , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[17] B. Zinman,et al. Alternative routes of insulin delivery , 2003, Diabetic medicine : a journal of the British Diabetic Association.
[18] L. Heinemann,et al. Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. , 2002, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[19] N Lotan,et al. Large porous particles for pulmonary drug delivery. , 1997, Science.
[20] A. Himmelmann,et al. The impact of smoking on inhaled insulin. , 2003, Diabetes care.
[21] Robert Langer,et al. Sustained release of insulin from insoluble inhaled particles , 1999 .
[22] I. Raz,et al. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. , 2005, Clinical therapeutics.
[23] D. Owens,et al. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes , 2006, Diabetologia.
[24] Lawrence Blonde,et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.
[25] H. Arnqvist,et al. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. , 2001, Diabetes care.
[26] T. Heise,et al. Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes , 2007, Diabetes, obesity & metabolism.
[27] M. Gänsslen,et al. Über Inhalation von Insulin , 2005, Klinische Wochenschrift.
[28] S. Clement,et al. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. , 2004, Metabolism: clinical and experimental.
[29] J. Davidson,et al. Factors Influencing the Absorption, Serum Insulin Concentration, and Blood Glucose Responses After Injections of Regular Insulin and Various Insulin Mixtures , 1981, Diabetes Care.
[30] S. Mudaliar,et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. , 2003, Diabetes care.
[31] 王姮,et al. Inhaled insulin , 2005 .
[32] J. Rosenstock,et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. , 2004, Diabetes care.
[33] L. Heinemann,et al. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects , 1994, Diabetologia.
[34] L. Fabbri. Pulmonary safety of inhaled insulins: a review of the current data , 2006 .
[35] D. Owens,et al. Absorption of Radiolabeled Soluble Insulin in Type 1 (Insulin‐dependent) Diabetes: Influence of Subcutaneous Blood Flow and Anthropometry , 1993, Diabetic medicine : a journal of the British Diabetic Association.
[36] J. DeVries. To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48:1988–1995 , 2006, Diabetologia.
[37] E. S. Albright,et al. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. , 2004, Diabetes care.
[38] D. Owens,et al. Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes , 2007, Diabetes Care.
[39] L Heinemann,et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. , 2000, Diabetes care.
[40] L. Heinemann,et al. Insulin glulisine: a faster onset of action compared with insulin lispro , 2007, Diabetes, obesity & metabolism.
[41] S. Skeie,et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. , 2003, Diabetes care.
[42] A. Dobs,et al. The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes. , 1998, Chest.
[43] W. Wein,et al. Postprandial Insulin Lispro: A new therapeutic option for type 1 diabetic patients , 1998, Diabetes Care.
[44] L. Heinemann,et al. Time‐action profile of the soluble, fatty acid acylated, long‐acting insulin analogue NN304 , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[45] J. Plank,et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. , 2005, Diabetes care.
[46] S. Mudaliar,et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. , 1999, Diabetes care.
[47] S. Heller,et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross‐over trial in people with Type 1 diabetes , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[48] A. Hamann,et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. , 2003, Diabetes care.
[49] T. Rönnemaa,et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. , 2004, Diabetes care.
[50] Dmitry Malkov,et al. Oral delivery of insulin with the eligen technology: mechanistic studies. , 2005, Current drug delivery.
[51] P. Brunetti,et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. , 2000, Diabetes.
[52] P. Home,et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. , 2004, Diabetes care.
[53] T. Quattrin,et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.
[54] A. Dornhorst,et al. Safety and efficacy of insulin detemir in clinical practice: 14‐week follow‐up data from type 1 and type 2 diabetes patients in the PREDICTIVETM European cohort , 2007, International journal of clinical practice.
[55] T. Pieber,et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy , 2007, Diabetic medicine : a journal of the British Diabetic Association.
[56] Y. Chien,et al. Novel methods of insulin delivery: an update. , 1998, Critical reviews in therapeutic drug carrier systems.
[57] J. Rosenstock,et al. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. , 2005, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[58] S. Ashwell,et al. Twice‐daily compared with once‐daily insulin glargine in people with Type 1 diabetes using meal‐time insulin aspart , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[59] J. Patton,et al. Clinical Pharmacokinetics and Pharmacodynamics of Inhaled Insulin , 2004, Clinical pharmacokinetics.
[60] R. Becker,et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. , 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[61] A. Tiengo,et al. Lower within‐subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes , 2005, Diabetes, obesity & metabolism.
[62] L. Heinemann,et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. , 2004, Diabetes.
[63] B. Frier,et al. Optimal Time of Administration of Insulin Lispro. Importance of meal composition , 1998, Diabetes Care.
[64] D. Howey,et al. [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin , 1994, Diabetes.
[65] L. Heinemann,et al. Injection-meal interval: recommendations of diabetologists and how patients handle it. , 1999, Diabetes research and clinical practice.
[66] I. Raz,et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. , 2004, Diabetes research and clinical practice.
[67] R. Elliott,et al. Parenteral absorption of insulin from the lung in diabetic children , 1987, Australian paediatric journal.
[68] T. Pieber,et al. Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies , 2007, Diabetes, obesity & metabolism.
[69] K. Hermansen,et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes , 2004, Diabetologia.
[70] S. Ashwell,et al. Optimal timing of injection of once‐daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal‐times , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[71] P. Brunetti,et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. , 1999, Diabetes care.
[72] M. Dreyer,et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[73] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[74] P. Kurtzhals. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir , 2004, International Journal of Obesity.
[75] A. Philotheou,et al. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[76] L. Heinemann,et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. , 2005, Diabetes care.
[77] J. Guevara-Aguirre,et al. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study , 2004, Diabetes/metabolism research and reviews.
[78] D. Russell-Jones,et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. , 2004, Clinical therapeutics.
[79] D R Owens,et al. Monomeric Insulins and Their Experimental and Clinical Implications , 1990, Diabetes Care.
[80] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[81] M. Ellmerer,et al. Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients , 2001, Diabetologia.